title: New therapeutic targets in the treatment of prostate cancer.
abstract: Androgen deprivation therapy has become the mainstay of the treatment of advanced prostate cancer, being used in every clinical setting of the disease, from neoadjuvant to metastatic disease. Despite success in controlling the disease in the majority of men, hormonal manipulations will eventually fail. New agents are being developed for patients with hormone refractory disease. Important advances in molecular oncology have improved our understanding regarding the cellular mechanisms that regulate cell death in the prostate. It is hoped that these new insights will lead to development of more efficacious and easy to tolerate therapies for cancer prostate. This review focuses on the current literature on tumor vaccines, angiogenesis inhibitors, antisense oligonucleotides, differentiation agents, cancer-specific genes, endothelial receptor antagonists, anti-apoptotic agents, agents acting on signaling pathways and androgen and estrogen receptors.
authors.affiliation: Department of Urology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow - 226 014, India.
authors.forename: Vivek
authors.initials: V
authors.lastname: Vijjan
authors.forename: Deepak
authors.initials: D
authors.lastname: Dubey
references.citation: Clin Cancer Res. 2001 Jul;7(7):1888-93
references.pmid: 11448901
references.citation: Int J Cancer. 1994 Oct 1;59(1):126-32
references.pmid: 7523313
references.citation: Cancer Res. 2001 May 1;61(9):3689-97
references.pmid: 11325840
references.citation: J Clin Oncol. 2003 Jan 1;21(1):123-8
references.pmid: 12506180
references.citation: J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):309-16
references.pmid: 8877724
references.citation: J Urol. 1999 Jan;161(1):173-5
references.pmid: 10037392
references.citation: Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6
references.pmid: 11685731
references.citation: Urology. 2005 May;65(5 Suppl):9-16; discussion 17
references.pmid: 15885273
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2171-80
references.pmid: 11956279
references.citation: Urology. 1998 Jul;52(1):72-81
references.pmid: 9671874
references.citation: Urology. 2004 Aug;64(2):311-5; discussion 315-6
references.pmid: 15302485
references.citation: Urology. 1999 May;53(5):1063-9
references.pmid: 10223507
references.citation: Clin Cancer Res. 2002 Aug;8(8):2530-5
references.pmid: 12171880
references.citation: Semin Oncol. 2001 Aug;28(4 Suppl 15):67-70
references.pmid: 11685732
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1260-9
references.pmid: 16489082
references.citation: Prostate. 1999 Apr 1;39(1):54-9
references.pmid: 10221267
references.citation: Clin Cancer Res. 2000 May;6(5):1632-8
references.pmid: 10815880
references.citation: Clin Cancer Res. 2001 May;7(5):1198-203
references.pmid: 11350884
references.citation: J Clin Oncol. 2005 Jan 20;23(3):455-60
references.pmid: 15659491
references.citation: BJU Int. 2006 Apr;97(4):691-7
references.pmid: 16536755
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3894-903
references.pmid: 11099318
references.citation: Physiol Rev. 2001 Jul;81(3):1269-304
references.pmid: 11427696
references.citation: Cancer Chemother Pharmacol. 1997;39(4):349-56
references.pmid: 9025776
references.citation: Clin Cancer Res. 2000 Mar;6(3):838-46
references.pmid: 10741705
references.citation: Cancer Res. 1990 Apr 15;50(8):2311-5
references.pmid: 2317818
references.citation: Cancer Chemother Pharmacol. 1998;41(2):133-9
references.pmid: 9443626
references.citation: Cancer Res. 2000 Feb 15;60(4):829-33
references.pmid: 10706088
references.citation: J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000
references.pmid: 12837835
references.citation: Urology. 2003 Nov;62(5 Suppl 1):34-43
references.pmid: 14607216
references.citation: J Immunol. 1998 Sep 15;161(6):3186-94
references.pmid: 9743387
references.citation: Clin Cancer Res. 2001 Dec;7(12):3920-7
references.pmid: 11751483
references.citation: BJU Int. 2005 Dec;96 Suppl 2:30-4
references.pmid: 16359436
references.citation: Prostate. 1999 Jan 1;38(1):73-8
references.pmid: 9973112